CD4 and non-small cell lung carcinoma: With respect epigenetic biomarkers of response, we reported for the first time a signature of DNA methylation in 301 CpGs, EPIMMUNE, that could be downscaled to the unmethylated state of a single CpG site in the transcription factor FOXP1, which regulates both quiescence in naive CD4+ cells [126], and Th follicular cells [127], as predictive of response to ICB in NSCLC patients [28].